Pfiz­er could end Lip­i­tor an­titrust saga in­volv­ing Ran­baxy with $93M set­tle­ment

Pfiz­er has of­fered $93 mil­lion to set­tle an an­titrust law­suit brought by drug dis­trib­u­tors al­leg­ing it worked with In­dia’s Ran­baxy Lab­o­ra­to­ries to de­lay sales of gener­ic ver­sions of a cho­les­terol drug.

Lip­i­tor, a statin first ap­proved in 1997, rose to block­buster sta­tus and made more than $12 bil­lion a year at its peak. The drug achieved $130 bil­lion in its first 14 years, mak­ing it the best-sell­ing med­ica­tion of its time.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER